Dtsch Med Wochenschr 2019; 144(08): 528-534
DOI: 10.1055/a-0807-7774
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

Hepatitis B und D: aktuelle und zukünftige Therapien

Current and Future Therapy of Hepatitis B and D
Frank Tacke
Further Information

Publication History

Publication Date:
15 April 2019 (online)

Mit 240 Millionen chronisch infizierten Betroffenen ist die Hepatitis-B-Virus (HBV) - Infektion weltweit eine führende Ursache für die Leberzirrhose und das Leberzellkarzinom. Zur Virusunterdrückung bei einer Infektion mit begleitender Hepatitis sind hochwirksame antivirale Medikamente verfügbar. Neue Therapieansätze versuchen, anstelle einer Virusunterdrückung eine Viruselimination zu erzielen.

Abstract

With approximately 240 million chronically infected people, hepatitis B virus (HBV) infection is a leading cause of cirrhosis and hepatocellular carcinoma in the world. Chronic HBV infection should be treated with antivirals, if either liver cirrhosis with detectable HBV DNA or relevant viral load (HBV DNA > 2000 IU/ml) and signs of liver damage (transaminase elevation, fibrosis, risk of liver cancer or similar) are present. The current standard therapy is a long-term treatment with nucleoside or nucleotide analogues such as entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide, while in selected cases interferon treatment (for 48 weeks) may be useful. Entecavir and the new drug tenofovir alafenamide (TAF) are to be preferred over tenofovir disoproxil fumarate in patients with concomitant renal insufficiency or osteoporosis. Pregnant women with high viral load (> 200 000 IU/ml) should be treated with tenofovir in the third trimester to minimize the risk of neonatal transmission (in addition to immediate active-passive immunization). In conditions of immunosuppression (e. g. chemotherapy, rituximab, anti-TNF), even a “healed” HBV infection may reactivate in a life-threatening manner, requiring prophylactic antiviral therapy in addition to testing for HBV in high-risk situations. The current therapies primarily achieve virus suppression, but rarely the loss of HBs antigen, which is considered a functional cure. New strategies such as discontinuation of long-term antiviral therapy with provoked reactivation and also completely new drugs are currently in clinical trials. The most serious form of viral hepatitis is the co-/superinfection of HBV with the delta virus (HDV). Standard therapy for delta hepatitis is pegylated interferon-alfa, but the approval of new drugs such as the HBV entry inhibitor Myrcludex is expected in the near future.

 
  • Literatur

  • 1 Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018; 3: 383-403 . doi:10.1016/S2468-1253(18)30056-6
  • 2 European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-398 . doi:10.1016/j.jhep.2017.03.021
  • 3 Honer ZuSiederdissen C, Maasoumy B, Cornberg M. New viral biomarkers for Hepatitis B: Are we able to change practice?. J Viral Hepat 2018; DOI: 10.1111/jvh.12993.
  • 4 Terrault NA, Lok ASF, McMahon BJ. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67: 1560-1599 . doi:10.1002/hep.29800
  • 5 Agarwal K, Brunetto M, Seto WK. et al. 96 weeks treatment of tenofovir alafenamide vs tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 2018; 68: 672-681 . doi:10.1016/j.jhep.2017.11.039
  • 6 Tacke F, Kroy DC. Treatment for hepatitis B in patients with drug resistance. Ann Transl Med 2016; 4: 334 . doi:10.21037/atm.2016.09.19
  • 7 Shirvani-Dastgerdi E, Winer BY, Celia-Terrassa T. et al. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol 2017; 67: 246-254 . doi:10.1016/j.jhep.2017.03.027
  • 8 Cornberg M, Protzer U, Petersen J. et al. Prophylaxis, diagnosis and therapy of hepatitis B virus infection – the German guideline. Z Gastroenterol 2011; 49: 871-930 . doi:10.1055/s-0031-1273462
  • 9 Wedemeyer H, Yurdaydin C, Dalekos GN. et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-331 . doi:10.1056/NEJMoa0912696
  • 10 Pan CQ, Duan Z, Dai E. et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. N Engl J Med 2016; 374: 2324-2334 . doi:10.1056/NEJMoa1508660
  • 11 Jourdain G, Ngo-Giang-Huong N, Harrison L. et al. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. N Engl J Med 2018; 378: 911-923 . doi:10.1056/NEJMoa1708131
  • 12 Reddy KR, Beavers KL, Hammond SP. et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215-219 quiz e216-217. doi:10.1053/j.gastro.2014.10.039
  • 13 Cornberg M. Hepatitis B – Ein Ausblick auf aktualisierte Leitlinien. Dtsch Med Wochenschr 2018; 143: 183-188 . doi:10.1055/s-0043-114048
  • 14 Lok AS, Zoulim F, Dusheiko G. et al. Hepatitis B cure: From discovery to regulatory approval. J Hepatol 2017; 67: 847-861 . doi:10.1016/j.jhep.2017.05.008
  • 15 Qiu K, Liu B, Li SY. et al. Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance. Aliment Pharmacol Ther 2018; 47: 1340-1348 . doi:10.1111/apt.14629
  • 16 Berg T, Simon KG, Mauss S. et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study. J Hepatol 2017; 67: 918-924 . doi:10.1016/j.jhep.2017.07.012
  • 17 Papatheodoridis G, Vlachogiannakos I, Cholongitas E. et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 2016; 63: 1481-1492 . doi:10.1002/hep.28438
  • 18 Yuen MF, Chen DS, Dusheiko GM. et al. Hepatitis B virus infection. Nat Rev Dis Primers 2018; 4: 18035 . doi:10.1038/nrdp.2018.35
  • 19 Xia Y, Liang TJ. Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of HBV Infection. Gastroenterology 2018; in press. DOI: 10.1053/j.gastro.2018.07.057.
  • 20 Bogomolov P, Alexandrov A, Voronkova N. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol 2016; 65: 490-498 . doi:10.1016/j.jhep.2016.04.016